Macropinocytosing human anti-CD46 antibodies and targeted cancer therapeutics
US12325755B2 · kind B2 · utility
0Cited by
5References
43Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 21, 2019 |
| Grant date | Jun 10, 2025 |
| Priority date | — |
| Expiry date | Dec 7, 2042 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In various embodiments human anti-CD46 antibodies that are internalizing and enter tumor cells via the macropinocytosis pathway are provided, as well as antibody-drug conjugates (ADCs) developed from these antibodies for diagnostic and/or therapeutic targeting of CD46-overexpressing tumors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.